Effect of Buspirone added to Typical Antipsychotics on Positive and Negative symptoms in schizophrenia

Effect of Buspirone added to Typical Antipsychotics on Positive and Negative symptoms in schizophrenia (a double blind, placebo controlled, randomized trial)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201106026691N1

Enrollment

Registered

2012-09-17

Start date

2012-04-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Typical Antipsychotics combined with Tablet Buspirone(30 mg/day) as intervention group for 6 weeks. Intervention 2: Typical Antipsychotics combined with Tablets placebo as control grou

Treatment - Drugs

Typical Antipsychotics combined with Tablet Buspirone(30 mg/day) as intervention group for 6 weeks

Typical Antipsychotics combined with Tablets placebo as control group for 6 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Age between 18-65; Diagnosis of Schizophrenia based on DSMIV-TR; Chronic Schizophrenia(over 2 years); Ongoing treatment with Typical Antipsychotics. Exclusion criteria:Allergic to Buspirone; Any chronic medical problem; Substance dependency; Any other Psychiatric Disorder in Axis I or II; Pregnancy or Breast feeding.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-6 after begining of treatment. Method of measurement: Positive and Negative Syndrome Scale(PANSS).	—

Secondary

Measure	Time frame
Headache. Timepoint: Baseline and weeks 2,4,6 after begining of treatment. Method of measurement: Check list of adverse effects.;Nausea. Timepoint: Baseline and weeks 2-4-6 after begining of treatment. Method of measurement: Checklist of adverse effects.;Palpitation. Timepoint: Baseline and weeks 2-4-6 after begining of treatment. Method of measurement: Checklist of adverse effects.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Fatemeh Sheikhmoonesi

Mazandaran University of Medical Sciences

fmoonesi@mazums.ac.ir+98 15 1328 5109

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026